Shares of Anika Therapeutics Inc. skidded lower after the Bedford company said that the Food and Drug Administration had upheld its decision against approving Anika’s osteoarthritis treatment, Monovisc. The company said it will schedule a meeting with the FDA and then decide on its next steps. Monovisc is designed to treat pain in patients who suffer from osteoarthritis of the knee. It has been on the market in Europe since 2008 and was approved in Canada in 2009.
Unlimited access to BostonGlobe.com for only 99 cents for the first 4 weeks.Sign up
Are you a home delivery subscriber?
Get FREE access as part of your print subscriptionStart Here
Contact us for help